New York University
Latest From New York University
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
University researchers will examine adenosine receptor modulator technology’s potential in C. difficile infection and atherosclerosis. CRISPR Therapeutics is partnering with University of Alabama-Birmingham to evaluate gene-editing procedures in Friedreich’s ataxia.
Collaboration with Washington University to co-develop therapies targeting apoliprotein A makes up part of Denali's big August push in Alzheimer's. Kleo gets global rights to two Yale antibody programs and raises Series A cash.
Combination therapies are the cornerstone of oncology, but the development model has been slow to shift to early testing of combinations of investigational drugs. The CoNNCT initiative aims to accelerate clinical testing of novel-novel combinations, and in doing so provide benefits for biopharma, clinicians and the cancer patients they serve.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.